Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Xencor Inc (XNCR)

Xencor Inc (XNCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,820,177
  • Shares Outstanding, K 56,721
  • Annual Sales, $ 40,600 K
  • Annual Income, $ -70,410 K
  • 60-Month Beta 1.39
  • Price/Sales 12.06
  • Price/Cash Flow N/A
  • Price/Book 3.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.44
  • Number of Estimates 4
  • High Estimate -0.32
  • Low Estimate -0.59
  • Prior Year 1.38
  • Growth Rate Est. (year over year) -131.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.70 +5.36%
on 02/25/20
37.25 -10.34%
on 02/11/20
-0.93 (-2.71%)
since 01/24/20
3-Month
31.70 +5.36%
on 02/25/20
42.08 -20.63%
on 12/09/19
-5.07 (-13.18%)
since 11/26/19
52-Week
27.75 +20.36%
on 03/14/19
46.33 -27.91%
on 08/06/19
+2.74 (+8.94%)
since 02/26/19

Most Recent Stories

More News
Xencor (XNCR) Reports Q4 Loss, Lags Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 9.62% and -47.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

XNCR : 33.31 (+3.80%)
Xencor: 4Q Earnings Snapshot

MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Monday reported a loss of $26.9 million in its fourth quarter.

XNCR : 33.31 (+3.80%)
Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss

Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.

UTHR : 105.97 (-6.10%)
PCRX : 44.85 (-3.09%)
XNCR : 33.31 (+3.80%)
BHC : 24.44 (-1.33%)
Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that it will release...

XNCR : 33.31 (+3.80%)
Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management...

XNCR : 33.31 (+3.80%)
Aimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb(R)7195 for the Development of Next-Generation Food Allergy Treatments

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an exclusive...

AIMT : 26.24 (+2.30%)
XNCR : 33.31 (+3.80%)
MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announces that it today has entered into a global collaboration and licensing agreement with Incyte Corporation to further develop...

MOR : 27.87 (-2.21%)
XNCR : 33.31 (+3.80%)
MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

XNCR : 33.31 (+3.80%)
INCY : 78.05 (+0.94%)
Gilead (GILD) Inks License Deal with Xencor for HIV Candidate

Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.

GSK : 41.95 (+1.13%)
GILD : 74.97 (+6.95%)
ALXN : 94.66 (-1.54%)
XNCR : 33.31 (+3.80%)
Xencor and Gilead Enter License Agreement for Use of XmAb(R) Antibody Technologies in Investigational Agents for HIV

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced...

GILD : 74.97 (+6.95%)
XNCR : 33.31 (+3.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade XNCR with:

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

2nd Resistance Point 35.55
1st Resistance Point 33.82
Last Price 33.31
1st Support Level 31.03
2nd Support Level 29.97

See More

52-Week High 46.33
Fibonacci 61.8% 39.23
Fibonacci 50% 37.04
Fibonacci 38.2% 34.85
Last Price 33.31
52-Week Low 27.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar